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Abstract 
We report a case of a giant melanoma on the
back with a very extreme Breslow thickness.
On physical examination a large odorous and
ulcerating tumour was seen adjacent to two
large  crusted  lesions,  probably  in  transit
metastases. In the right and left axilla enlarged
lymph nodes were palpated. The patient under-
went salvage surgery consisting of a complete
wide excision of the tumors on the back as well
as  axillary  lymph  node  dissection  on  both
sides.  Histopathology  showed  a  malignant
melanoma with a Breslow thickness of 48 mm.
Four of fifteen nodes in the right axilla and one
of nine nodes in the left axilla, were positive
for metastatic disease. Also various in transit
and subcutaneous metastases were found in
the wide excision specimen. The interest of
our  observation  relies  in  the  rarity  of  a
melanoma  with  such  an  extreme  Breslow
thickness and the difficulty in performing ade-
quate palliative therapy that offers quality of
life by means of tumor control.
Introduction 
Today,  most  melanoma  patients  are  diag-
nosed  early  with  a  low  Breslow  thickness.1
However,  patient  delay  can  be  an  important
factor for melanoma to grow rapidly.
The incidence of cutaneous melanoma has
risen rapidly in the last decades and estimates
predict a further increase in the next years. In
the Netherlands for example, the number of
melanoma  patients  increased  from  2400
patients in 2000 to 3500 in  2005, suggesting
that the predicted number of 4800 patients in
2015 is an estimation that is too low.2
The incidence of thin melanomas (Breslow
thickness  ≤1.0  mm)  has  increased  as  was
shown in a recent Dutch study over the period
1980-2002.3 These  observations  reflect  a
greater  patient  and  physician  awareness  to
recognize early melanoma with consequently a
higher cure rate. Among the well known prog-
nostic factors, such as ulceration, mitotic rate
and sentinel lymph node status, Breslow thick-
ness remains the most important predictor of
long term survival.4,5 Patients diagnosed with
thick melanomas (Breslow thickness ≥4 mm)
are at bad risk. 
Case Report 
A 56-year old woman without a medical his-
tory was referred by her general physician to
our  outpatient  department  because  of  three
large lesions on the back which had grown sig-
nificantly in the last weeks.  On physical exam-
ination a large ulcerating odorous skin tumour
was found on the back measuring 8 by 6 cm.
Adjacent to it two additional crusted lesions
were noted measuring 4 and 1.5 cm respective-
ly  (Figures  1  and  2).  Enlarged  lymph  nodes
were palpated in the right and left axilla and on
the  back  two  subcutaneous  nodules  were
appreciated.  Biopsy  of  the  largest  tumor
showed  a  malignant  melanoma.  Although  a
chest X ray was negative for metastases as well
as a negative abdominal ultrasound, the serum
LDH was increased to 1140 U/L which was very
suspect for distant metastasis. In order to per-
form good palliative care it was decided to treat
the local tumor aggressively with surgery. The
three  tumors  were  excised  en  block  in  one
prep rate and a combined lymph node dissec-
tion of both axillae was performed. A split skin
graft (SSG) was used to cover the wound on
the back. Histopathology revealed a radically
removed ulcerating malignant melanoma with
a Breslow thickness of 48 mm. Four of fifteen
nodes in the right axilla and one of nine nodes
in the left axilla were tumour positive. In addi-
tion various in transit metastases were found
in the wide excision specimen of which the
largest was 3.5 cm in diameter. Ten weeks later
after  recovering  from  surgery  before  being
able to commence with systemic chemothera-
py  patient  developed  multiple  and  painful
nodes in the lower right neck region. Because
she became critically ill local radiotherapy was
omitted and she died two weeks later, unex-
pectedly. 
Discussion 
The interest of this case relies in the rarity
of the extreme Breslow thickness and the diffi-
culty to perform appropriate salvage treatment.  
In the database of the Netherlands Cancer
Registry only one other melanoma with this
magnitude of thickness (70 mm) is document-
ed in the period 1994-2005.6 Thick melanomas
(>4 mm) are relatively common. In the final
version  of  the  AJCC  (American  Joint
Commitee on Cancer) melanoma staging 14%
of the included 17.600 melanoma patients had
a  melanoma  with  a  Breslow  thickness  >4
mm.4  However, giant melanomas of 48 mm
are rarely encountered. To our knowledge, this
is one of the largest melanoma’s described in
literature.7
Patients  who  present  with  thicker
melanomas are generally of later age.8,9 One of
the  reasons  for  this  could  be  a  decreased
awareness in elderly patients combined with
more  difficulties  to  recognize  or  detect
changes of their skin. Also self negligence and
fear of visiting a doctor may be reasons for
delay  in  actually  visiting  a  physician.8 Our
patient, for example, had never visited a gener-
al practitioner before.
Despite a normal chest X-ray and a negative
abdominal  ultrasound  most  probably  our
patient  had  disseminated  disease  when  she
first presented. The serum LDH at first consul-
tation was increased to 1140 U/L which is very
suspect for distant metastasis.  
Notwithstanding  this,  surgery  was  chosen
in order to achieve palliative local tumour con-
trol.  This  local  intervention  resulted  in  3
months of relatively acceptable quality of life. 
When melanoma patients present with an
advanced stage of local disease as in the above
described case, the consulting physician has to
think twice before starting therapy with a cur-
ative intent. The answer for curative therapy
in melanoma in general has to be sought in
early  recognition  and  early  presentation  as
opposed to the situation of our patient. 
After having performed the biopsy together
with  the  elevated  LDH  and  palpable  axillary
lymph nodes on both sides the patient could
already be staged as T4N2M1c. These findings,
bringing her in a palliative situation, made a
PET-CT  scan,  with  the  aim  to  prove  distant
metastases, a needless investigation. 
Giant  melanomas  like  these  are  rarely
encountered. With the aim of tumor control,
principles of wide surgical excision and thera-
peutic  lymph  node  dissection  can  still  be
applied  for  giant  melanomas.10 Despite  the
size  of  a  giant  melanoma,  the  work  up  and
principles of wide surgical excision remain the
same. There is no benefit with a greater than
two-centimeter  margin  in  melanomas  with
thickness greater than four millimeters, as the
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risk of dying from metastatic disease is greater
than the risk of recurrence.11
Other  therapy  options  instead  of  salvage
surgery could be radiation therapy or palliative
chemotherapy.  For  radiation  therapy  in  this
case the tumor surface would have been too
large with a very low response rate. According
to the Dutch melanoma guideline the standard
palliative chemotherapy should be DTIC with a
very low response rate.12
Treatment  results  for  stage  IV  melanoma
remain unsatisfactory with a one year survival
of 33%.4 No systemic therapy has demonstrat-
ed  to  affect  overall  survival,  although  the
recent  immunotherapy  with  Ipilimumab  and
the  introduction  of  the  BRAF  pathway
inhibitors have shown promising results.13,14
In conclusion, despite advances in adjuvant
therapies, the primary treatment for a giant
melanoma  can  remain  surgical  even  when
there is no curative intent. 
In this case, treatment was performed with
palliative  intent  as  time  was  precious  and
unnecessary  diagnostic  research  was  to  be
avoided.  Consequently,  since  the  described
melanoma tumour was too large for radiother-
apy, salvage surgery was chosen as the best
palliation treatment and for local control of the
primary  tumour  and  the  axilary  lymph  node
metastases. Adjuvant palliative systemic treat-
ment was planned afterwards but unfortunate-
ly this was cancelled when the patient present-
ed  with  locoregional  recurrent  disease  and
became too weak for further palliative therapy. 
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Case Report
Figure 1. A giant melanoma on the back.
Figure 2. A ulcerating tumor on the back.